title: Clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator artery thrombolysis on acute cerebral infarction.
abstract: This study aims to explore the clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator (rt-PA) artery thrombolysis on acute cerebral infarction (ACI). One hundred and thirty-two cases of ACI patients were randomly divided into an experimental group (66 patients) and a control group (66 patients). The experimental group was treated with mechanical fragmentation combined with rt-PA artery thrombolysis method, while the control group was treated with only the rt- PA artery thrombolysis method. All the patients had their basic information recorded. A computational analysis on National Institutes of Health Stroke Scale (NIHSS) scores, curative effect and bleeding data was carried out. The results showed that in the experimental group the curative effects were better and there were fewer complications. Accordingly, we conclude that mechanical fragmentation combined with rt-PA artery thrombolytic method is a safe and reliable therapy with significant curative effects. It improves the NIHSS scores of the patients markedly and reduces the incidence of subsequent pneumonia.
authors.affiliation: Department of Pharmacy, Cangzhou Central Hospital, Cangzhou, China.
authors.forename: X F
authors.initials: XF
authors.lastname: Jia
authors.affiliation: Department of Neurology, Cangzhou Central Hospital, Cangzhou, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Hong
authors.affiliation: Department of outpatient nursing, Cangzhou Central Hospital, Cangzhou, China.
authors.forename: J H
authors.initials: JH
authors.lastname: Fan
authors.affiliation: Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
authors.forename: Y M
authors.initials: YM
authors.lastname: Zhang
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001925:Brain Damage, Chronic / Q000209:etiology / Q000517:prevention & control; D002544:Cerebral Infarction / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D008297:Male; D061185:Mechanical Thrombolysis; D008875:Middle Aged; D011014:Pneumonia / Q000453:epidemiology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012720:Severity of Illness Index; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator